50 minutes ago
Raja Atreya, MD, reviews adverse events and treatment discontinuation through week 26 in the real-world UPlift study.
1 hour ago
Evangelos Oikonomou, MD, discusses the newly-developed deep-learning model and how it effectively characterizes epicardial adipose tissue and cardiovascular risk.
1 hour ago
UPlift interim data show 70.2% achieved clinical response within 12 weeks, with a median time to first response of 13 days.
4 hours ago
Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.
20 hours ago
Mike Sharma, MD, MSc, discusses how asundexian’s approval revolutionizes secondary stroke prevention – and may provide a pathway to treat many more conditions.